Robert Lechleider Sells 55,000 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) insider Robert Lechleider sold 55,000 shares of Immunome stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $19.85, for a total value of $1,091,750.00. Following the completion of the sale, the insider directly owned 15,805 shares in the company, valued at approximately $313,729.25. This represents a 77.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Immunome Stock Up 0.7%

IMNM stock opened at $21.19 on Wednesday. The business has a 50 day moving average price of $21.02 and a two-hundred day moving average price of $21.74. The company has a market cap of $2.40 billion, a price-to-earnings ratio of -8.90 and a beta of 2.04. Immunome, Inc. has a twelve month low of $7.96 and a twelve month high of $27.65.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.12. On average, equities research analysts anticipate that Immunome, Inc. will post -2.06 EPS for the current fiscal year.

Institutional Trading of Immunome

Hedge funds have recently modified their holdings of the stock. KBC Group NV acquired a new position in Immunome in the 1st quarter valued at about $60,000. Strs Ohio acquired a new stake in Immunome during the fourth quarter worth approximately $64,000. Assetmark Inc. lifted its position in Immunome by 46.6% during the first quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock worth $99,000 after acquiring an additional 1,442 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new stake in shares of Immunome during the fourth quarter worth approximately $121,000. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after acquiring an additional 2,909 shares during the period. Institutional investors and hedge funds own 44.58% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on IMNM. Stephens dropped their price target on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 4th. Barclays initiated coverage on shares of Immunome in a research report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Immunome in a research note on Wednesday, May 13th. Wall Street Zen cut shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Finally, Wedbush reiterated an “outperform” rating and issued a $31.00 target price on shares of Immunome in a research note on Friday, June 12th. Twelve research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Immunome currently has a consensus rating of “Moderate Buy” and an average price target of $33.17.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.